Purpose The aim of this study was to identify prematurely ended phase III clinical trials (CTs) and the proportion of such trials among all phase III CTs, review the reasons for the premature discontinuation of the CT, determine whether a data monitoring committee (DMC) was involved in this decision-making process, identify the data source on which the decision was based and review the consequences of the premature ending for product development. An additional aim was to identify risk factors for a premature ending. Methods Prematurely ended phase III CTs in Sweden between 2002 and 2008 were identified by database searches. Identified trials were reviewed for treatment tested, study design, reasons for the premature ending, data source on which the decision was based and existence of and recommendation from a DMC. Three randomly selected but not prematurely ended control trials were identified, starting 1 May 2004, that were matched on the basis of application year. Results A total of 84 phase III CT applications (8%) were prematurely ended during the study period. Most trials were ended due to safety and/or efficacy concerns. A DMC was more common among trials in which mortality was the primary endpoint and oncology trials. A recommendation from the DMC to terminate the trial was most likely in the case of combined safety-and efficacy-related issues arising from within the trial. Possible risk factors for a premature ending included mortality as an endpoint, obesity as an indication and a longer than planned study duration. Approximately 30% of prematurely ended trials with active substances that did not have a marketing authorization at the time of the clinical trial application resulted in the discontinuation of further development of the substance. Conclusions The DMCs in the phase III CTs reviewed here were used in accordance with guidelines. The use of DMCs was associated with possible risk factors for a premature ending and numerically, but not significantly associated with a premature ending.
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Background
Phase III is the last phase of the drug development process [1] before a new marketing authorization application can be submitted. Phase III clinical trials are intended to verify the clinical efficacy and characterize the safety profile of a drug in a therapeutic indication. Whilst it is important that such trials are not ended prematurely before efficacy has been unequivocally demonstrated, it is equally necessary to avoid continued exposure to a harmful drug. In order to accommodate these needs without risking the scientific integrity of the trial, the review of data from ongoing clinical trials is usually delegated to an independent external committee or advisory board which makes recommendations to the sponsor of the trial [2] . Recently, both the EU and the Federal Drug Administration (FDA) have published guidelines on the use of such committees in clinical trials [3, 4] . For consistency, the term data monitoring committee (DMC) will be used throughout this document.
The aim of this investigation was to identify phase III clinical trials which were ended prematurely in Sweden in the years [2002] [2003] [2004] [2005] [2006] [2007] [2008] , to review the reasons for the premature discontinuation of the trial and to find out whether or not a DMC had been involved in the decisionmaking process and if the data on which the decision to stop the trial came from the trial itself or from outside of the trial. Additional aims were to identify the proportion of phase III clinical trials that were prematurely ended and to review the consequences of the premature ending for the tested product and its indication.
Methods
In Sweden, approval from the Medical Products Agency (MPA) has been obligatory for all clinical trials involving human subjects since 1988. Limited administrative information related to the clinical trials is stored in the databases LVIS-C (for clinical trials before 1 May 2004) and Documentum (for clinical trials from 1 May 2004 onwards). The European Clinical Trial Directive (EU-CTD) was introduced for all clinical trial applications since 1 May 2004. The European database EudraCT also contains administrative information. Information that can be found in the databases include, for example, application date, title of the trial, trial phase (only LVIS-C and EudraCT), name (s) of the investigational medicinal product(s), date(s) of request(s) for supplementary information, name of sponsor, name(s) of investigators, date(s) when the trial was approved or rejected and status of the trial (approved, interrupted, completed).
Phase III clinical trials that were prematurely discontinued between 1 January 2002 and 31 December 2008 were identified in LVIS-C, Documentum and EudraCT. Since trial phase is not included in Documentum, all applications for phase III clinical trials in Sweden since 1 May 2004 were identified in EudraCT, and records were matched with the same records from Documentum. In the databases LVIS-C and Documentum, the current status of the trial, i.e. "approved", "interrupted" or "completed" is indicated. All trials with the status "interrupted" were reviewed, and trials that were permanently ended were included in the study. In addition, since the status of a trial changes to "completed" after the final study report has been submitted, the EudraCT database was searched for the term "premature end" and for reasons for a "premature end" (these reasons are "safety", "lack of efficacy", "the trial has not commenced" and "other"), and the LVIS-C database was searched for spontaneous notifications using looseending text strings (indicated by *) that may indicate a premature ending ("stop*", "avbr*", "prematu*", "förtid*" and "säkerhet*). All trials retrieved by the searches were reviewed in order to identify trials that were permanently and prematurely ended.
The review was restricted to trials that were both approved and had started patient inclusion in Sweden. A prematurely ended trial was defined as a trial that was ended prior to the last treatment of the last patient according to the last version of the protocol. The reasons for a premature ending were classified as due to safety alone, efficacy alone, both safety and efficacy and other reasons including, for example, slow patient recruitment, a lower than expected endpoint rate, changes to regulatory guidelines in such a way that the trial hypothesis was no longer of interest, etc. A safety issue was considered in the case of an overrepresentation of serious adverse events or reactions, even if not formally statistically significant, provided that (1) the pharmacological mechanism of action made a causal relationship likely and (2) the safety issue was not outweighed by other advantages. A safety issue was also considered if the tested treatment had the opposite to the expected effect on the primary endpoint in the absence of any benefit. A smaller than expected effect or the opposite effect on the primary endpoint was considered to be a lack of efficacy issue. A greater than expected effect on the primary endpoint was considered as an unexpected positive efficacy finding. The categorization was based on an assessment of the overall profile of the tested treatment.
All prematurely ended trials were further reviewed with regard to the tested treatment, the type of control group used in the trial (placebo, active treatment, another dose or regime of the study treatment, background, standard or no treatment or no control group) and the existence of a DMC. It was noted if the primary endpoints concerned mortality.
For clinical trial applications during the years 2002-2006 the proportion of all phase III trials that were prematurely ended until 31 December 2008 was calculated. This was not done for clinical trial applications during the years 2007-2008 due to an insufficient period of follow-up that was considered likely to result in a significant number of prematurely ended trials in the years to come.
In order to evaluate the impact of the premature ending on the study duration and to identify possible risk factors for a premature ending, for each prematurely ended trial we identified a total of three randomly selected phase III control trials that were not prematurely ended until 31 Fisher's exact tests and the Mann-Whitney U test were performed to compare groups of interest. A two-sided p value of <0.05 was considered to be statistically significant.
Results
A total of 84 prematurely ended phase III clinical trials were identified during the years 2002-2008 (Fig. 1) . The trials had started up to 7 years before the premature ending ( Table 1) . Almost all premature endings had taken place within the first 3 years after start of the trial (77/84; 92%), with the highest observed frequency during the second year (38/84; 45%). The reasons for the premature ending were safety alone in 28 cases (33%), safety and lack of efficacy in 25 cases (30%), lack of efficacy alone in 12 cases (14%) and other reasons in 19 cases (23 %).
The percentage of prematurely ended phase III trials in relation to the total number of phase III clinical trial applications during the years 2002-2006 is shown in Table 2 .
Oncology was the largest treatment indication among prematurely ended phase III trials (24%; 20/84). Mortality was included as a primary endpoint in 29 trials (35%).
A total of 57 prematurely ended phase III clinical trials had a DMC. The distribution of the existence of a DMC in relation to different factors is shown in Table 3 . In total, the DMC recommended the termination of 30 trials, with the decision for trial discontinuation based on safety alone, lack of efficacy alone or on combined safety and lack of efficacy issues, with the exception of one trial. Table 4 shows the distribution of reasons for termination (excluding reasons for termination other than safety and/or efficacy) in relation to the existence of a DMC and to the data source upon which the decision was based. No trial was ended prematurely due to unexpected positive benefit.
Compared with control trials, factors that appeared to be associated with a premature ending included treatment indication, mortality as an endpoint and planned study duration. Among prematurely ended clinical trials, obesity as an indication was more common (10/48 vs. 2/144; p< 0.0001), whereas unusual indications (with fewer than five trials in our material) were less common (27/144 vs. 2/48; p=0.02). Mortality as an endpoint was twice as common (33%; 16/48 vs. 17%; 24/144; p=0.02) and the planned study duration was slightly longer among prematurely ended clinical trials (median 30 months; 25th to 75th percentile 24-42 months vs. 24 months; 25th to 75th percentile 14-46 months; p=0.03). For other factors, no significant differences could be observed, including design of the study and the existence of a DMC or active substance with or without a marketing authorization at the start of the Situations when a DMC was used were similar among prematurely ended trials and control trials, with no significant differences observed. Despite the longer planned study duration, the real study duration was shorter among prematurely ended clinical trials (Fig. 2) . Control trials that were still ongoing at the end of our study were censored. A total of 36 trials (42%) concerned substances that were approved as medicinal products at the time of the clinical trial application, and 49 trials (58%) concerned substances that had not yet been approved at the time of the clinical trial application. A total of six trials with already approved substances (17%; 6/36) were prematurely terminated following the withdrawal of the product from the market due to safety issues (n=3 for rimonabant, n =2 for rofecoxib and n=1 for melagatran/ximelagatran). In five trials with already approved substances (14%; 5/36) within unapproved treatment indications, a decision to discontinue pursuing the indication appeared to have been taken as a result of the trial, including prevention of sporadic colorectal polyps in patients without a history of familial adenomatous polyposis (n=1 for celecoxib), prevention of major coronary events in postmenopausal women (n=1 for raloxifen), prevention of diabetic retinopathy (n=1 for sandostatin), treatment of climacteric symptoms in patients with a history of breast cancer (n=1 for tibolone) and treatment of non-haemophiliac patients with bleeding refractory to standard treatment following major trauma (n=1 for recombinant factor VIIa). Of 49 trials with substances that had not yet been approved at the time of the clinical trial application, there were two trials (4%; 2/ 49) with substances that later became approved and were withdrawn from the market due to safety issues (n=1 rimonabant, n =1 rofecoxib). The phase III trials were prematurely ended after the market withdrawals. A further 16 trials (33%; 16/49) concerned ten substances that were discontinued prior to the application for a marketing authorization. The use of a DMC seemed to adhere with recommendations in the DMC guidelines as all trials investigating mortality as a primary endpoint had a DMC (29 prematurely ended trials and 24 control trials), as did all trials investigating cannabinoid antagonists due to the psychiatric adverse event profile of these agents (10 prematurely ended trials and 2 control trials) and all except one oncology trial (all 20 prematurely ended trials and 24/25 control trials). Overall, the use of a DMC was quite high, encompassing as much as 71% of prematurely ended phase III trials and 56% of control trials with an application date from 1 May 2004 onwards. As expected, a DMC was less common in trials that had no control group.
Discussion
In trials that had a DMC, the DMC was more likely to recommend termination of the trial for combined safety and lack of efficacy issues compared with issues related to only to safety or only to a lack of efficacy. Among trials with a DMC that were stopped due to a lack of efficacy-only issues, the recommendation to stop the trial was more likely to be made by the DMC if data arose from the trial itself than if data arose from outside of the trial. The same tendency was also noted for safety issues. A possible explanation for this finding may be that DMCs are not always completely informed of results from other ongoing or recently completed trials with the tested product. Another possible explanation is that DMCs may be more focused on information from within the trial than on information from outside the trial. Preferably, DMCs should be continuously informed of all results of relevance for their ongoing assessment. The one trial that was stopped for combined safety and efficacy issues without the recommendation of a DMC deserves some attention. The sponsor had analysed the data and made the decision prior to informing the DMC; a procedure which places the role of the DMC somewhat in doubt. In all instances, the sponsor adhered to the recommendations of the DMC.
Of the 29 trials that the DMC recommended be prematurely discontinued, 15 were stopped as a consequence of having fulfilled pre-specified criteria for futility at interim analysis and 14 trials were stopped without having fulfilled such criteria. No interim analysis was planned in seven of those 14 trials, while in the remaining seven trials an interim analysis was planned. However, in two of the latter seven cases the evaluation was triggered by results from other trials and hence did not take place at the planned time of the interim analysis. In all of these seven cases the DMC recommended that the trial be stopped even though formal statistical criteria were not met.
It was difficult to determine what impact, if any, the prematurely terminated trial had on the development of the tested substance. However, in at least 30% of prematurely ended trials concerning active substances that did not have a marketing authorization at the start of the trial, further development of the active substances was discontinued. Of the trials with marketed substances, 19% were prematurely ended due to withdrawal of the substance from the market for safety reasons. Among trials with approved substances, ten (31%) were stopped for safety reasons without a subsequent withdrawal of the marketed product. Marketing authorization status did not appear to be associated with the risk of a premature ending, as the proportion of trials with active substances with and without a marketing authorization was similar among prematurely ended and control trials.
Surprisingly, we did not identify any trials that were ended prematurely due to favourable results, which may be in contrast with findings from previous publications [5, 6] . However, it is our genuine experience that stopping a trial for benefit is extremely rare. In the publication by Montori et al. only 143 out of 58,357 published trials (0.2% or 2/1000) were stopped for benefit. The limited number of phase III trials investigated in this study may therefore explain why no such trial was identified, taking also into account biases associated with the publication of clinical trials. It is also possible that agreed protocol changes are made in case of trials with unexpected benefit in such a way that a premature ending according to our definition can be avoided. This possibility is supported by another publication of early reporting of positive trial results by Korn et al. in which follow-up results were later published for 22/27 trials (81%) [7] . We did identify two of the 25 trials reported to have been stopped early for benefit by Trotta et al. [5] . In both cases, beneficial interim results had been published. The trials, which were both open-label, were continued in accordance with the protocol. They did, therefore, not fulfil our definition of a premature ending. None of the trials reported by Korn et al. [7] had been carried out in Sweden. It may be noted that according to the new EU guidance document related to the application of clinical trials with medicinal products for human use that was published in the spring of 2010, only premature endings related to safety concerns have to be reported.
Our study has a number of limitations. Firstly, the study was carried out only in Sweden during a limited time period, and results may not be representative for other countries or other periods of time. Secondly, the study has an exploratory character, and no corrections for multiple comparisons have been made in the analyses. Some of the findings in the study may therefore have arisen purely by chance. Finally, we were only able to compare prematurely ended trials with control trials for those trials that had an application date of 1 May 2004 or later. For this reason, our study had limited power to study factors that might be related to the risk of a premature ending. The size of the control group in our study (three controls per case) was selected bearing in mind that the incremental increase in statistical power decreases for each added control per case. Almost, no further gain in power is achieved with≥4 controls per case. In relation to the achieved increase in power, three control trials for each prematurely ended trial seemed to adequately balance the workload.
Conclusion
Between 5 and 14% of phase III clinical trials that had been submitted to the Medical Products Agency during each of the years from 2002 to 2006 were prematurely ended. Most of the trials were ended due to safety and/or efficacy concerns. No trial was ended due to unexpected favourable results. A DMC was in place in two-thirds of prematurely ended trials, and in over half of the control trials that were not prematurely ended, there was no statistically significant difference between the groups. The use of a DMC was more common among trials investigating mortality as the primary endpoint and oncology trials. The DMC was more likely to recommend terminating the trial for combined safety-and efficacy-related issues than for issues related to only safety or only efficacy. Combined safety-and efficacyrelated issues, in contrast to safety-alone-or efficacy-alonerelated issues, were mainly based on information from the trial itself. Compared with phase III trials that were not prematurely ended, factors that were overrepresented among prematurely ended trials included mortality as endpoint, obesity as indication and planned longer study duration. Unusual indications (with fewer than 5 trials in our material) were, in contrast, underrepresented among prematurely ended trials. Despite the anticipated longer study durations for prematurely ended trials, actual study durations were shorter. Approximately 30% of prematurely ended trials with active substances that did not have a marketing authorization at the time of the clinical trial application resulted in the discontinuation of further development of the substance.
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